Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cellular uptake of antisense oligonucleotides.

A M Tari1, G Lopez-Berestein

  • 1Department of Bioimmunotherapy, The University of Texas MD Anderson Cancer Center, Houston 77030, USA. atari@mdanderson.org

Current Opinion in Investigational Drugs (London, England : 2000)
|March 14, 2002
PubMed
Summary

Antisense oligonucleotides (AS ONs) block protein production by targeting mRNA. This review examines cell receptors involved in AS ON uptake and their bioavailability after in vivo administration.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver.

Oncogene·2020
Same author

Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP).

Oncogene·2017
Same author

Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p.

Oncogene·2016
Same author

Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4.

Oncogene·2016
Same author

Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer.

Oncogene·2016
Same author

Therapeutic silencing of HPV 16 E7 by systemic administration of siRNA-neutral DOPC nanoliposome in a murine cervical cancer model with obesity.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2016

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Pharmacology

Background:

  • Antisense oligonucleotides (AS ONs) are short nucleic acid sequences designed to inhibit gene expression by binding to target messenger RNA (mRNA).
  • Cellular uptake of AS ONs is primarily mediated by endocytosis, a process involving specific cell surface receptors.
  • The efficiency and specificity of AS ON delivery depend heavily on the type and expression levels of these receptors, which vary significantly across different cell types.

Purpose of the Study:

  • To review the characteristics of various cell surface receptors involved in the in vitro uptake of antisense oligonucleotides.
  • To discuss the mechanisms of receptor-mediated endocytosis for AS ONs.
  • To explore the bioavailability and cellular uptake of AS ONs following in vivo administration.

Main Methods:

  • Literature review of in vitro studies characterizing receptors involved in AS ON cellular uptake.
  • Analysis of data on receptor expression patterns in different cell types.
  • Review of studies investigating AS ON bioavailability and tissue distribution in vivo.

Main Results:

  • Identification and characterization of diverse cell surface receptors mediating AS ON endocytosis.
  • Demonstration that receptor characteristics and expression levels are cell-type specific, influencing AS ON uptake.
  • Overview of factors affecting AS ON bioavailability and cellular penetration in vivo.

Conclusions:

  • Receptor-mediated endocytosis is a critical pathway for cellular delivery of antisense oligonucleotides.
  • Understanding receptor characteristics is essential for optimizing AS ON delivery and therapeutic efficacy.
  • Further research into receptor-ligand interactions can enhance the development of targeted AS ON therapies.

Related Experiment Videos